CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, D0
Investor Presentation
Brepocitinib VALOR Phase 3 Study in DM on Track for 2025 Data Readout; Investor Event Highlights
Annual Report to Security Holders
News
Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
Reg. FD
Changes in Board, Management or Compensation
Q1
FY 2024
Q3
Q2
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities